Alligator Bioscience Ab · OMXSTO:ATORX

Alligator Bioscience Ab — Carnegie Healthcare Seminar 2016

16 slides from Alligator Bioscience Ab's conference presentation, Mar 17, 2016

  1. Slide 1: Company presentation

    Company presentation Per Norlén CEO, CMO Carnegie Healthcare Seminar 17 March 2016 Strictly private and confidential

  2. Slide 2: Disclaimer

    Disclaimer This presentation regarding Alligator Bioscience AB (“Alligator”) and its contents are confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, by any medium or for any purpose. This presentation doe

  3. Slide 3: Alligator Bioscience in brief

    Alligator Bioscience in brief KEY INVESTMENT HIGHLIGHTS HISTORY OF ASSET GROWTH Agonistic antibodies for tumor-directed immuno-oncology 2015 ADC-1013 in clinical phase I Well-positioned immuno-oncology pipeline 2013 ALLIGATOR-GOLD® mAb library Janssen Biotech Major out-licensing deal with Janssen Bi

  4. Slide 4: Tumor-directed immuno-oncology

    Tumor-directed immuno-oncology Metastases Tumor SYSTEMIC IMMUNOTHERAPY TUMOR-DIRECTED IMMUNOTHERAPY INTRA-TUMORAL INJECTION TUMOR-LOCALIZING ANTIBODIES General immune activation with potential Tumor-selective immune activation Tumor-selective immune activation severe toxicity with less systemic toxi

  5. Slide 5: Fully integrated technology platforms

    Fully integrated technology platforms ALLIGATOR-GOLD® FIND® ALLIGATOR-GOLD® FIND® fully human single-chain library protein optimization technology D I V E R S I T Y > 1 0 10 OPTIMIZATION SUPERIOR COMPOUND  Increased tumor retention  Increased potency  Improved safety profile  Decreased antigenic

  6. Slide 6: Rapid development within the field of immuno-oncology

    Rapid development within the field of immuno-oncology Immunotherapy potentially improves long-term survival Strong uptake in first generation products Illustrative SALES DEVELOPMENT FIRST GENERATION IMMUNO-ONCOLOGY US$ millions Survival 100% 2 634 566 1 369 942 960 706 360 1 126 0% Time 2011 2012 20

  7. Slide 7: Well-positioned and promising drug development pipeline

    Well-positioned and promising drug development pipeline Development pipeline focusing on agonistic monospecific and bispecific antibodies targeting TNFR superfamily PROJECT MOLECULE TARGET LEAD OPTIMIZATION POC IN-VIVO PRE-CLINICAL PHASE I PHASE II ADC-1013 Monospecific CD40 ADC-1015 Bispecific OX40

  8. Slide 8: ADC-1013: CD40 is a key immuno-oncology target

    ADC-1013: CD40 is a key immuno-oncology target ADC-1013 Mode of Action Co-stimulating receptors ANTIGEN-PRESENTING CELL T CELL ANTIGEN-PRESENTING CELL T CELL PDL1 or PDL2 ? + ADC-1013 PDL1 or PDL2 PD1 – CD40 CD80 or CD86 CD28 + CD80 or CD86 CTLA4 – B7RP1 ICOS + B7-H3 ? – B7-H4 ? – T cell HVEM BTLA –

  9. Slide 9: Antibody based immuno-oncology drugs in clinical development

    ADC-1013: Antibody based immuno-oncology drugs in clinical development Selection of antibody based immuno-oncology drugs in clinical development Company Drug Indication Phase Target Roche (Genentech) atezolizumab NSCLC, bladder, renal, etc III PD-L1 AstraZeneca (MedImmune) durvalumab NSCLC, H&N, bla

  10. Slide 10: ADC-1013: Systemic anti-tumor effects (1/2)

    ADC-1013: Systemic anti-tumor effects (1/2) Anti-tumor immune response Two tumors are implanted under One of the tumors receives towards both tumors can be the skin ADC-1013 treatment obtained Source: Company information 10

  11. Slide 11: ADC-1013: Systemic anti-tumor effects (2/2)

    ADC-1013: Systemic anti-tumor effects (2/2) Results from pre-clinical evaluation of ADC-1013 in treatment of B16 melanoma 350 300 250 Tumor volume (mm³) 200 150 100 50 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Time (days) Ctr lgG (right tumor) Ctr lgG (left tumor) ADC-1013 (right tumor) ADC-1

  12. Slide 12: ADC-1013: Long term immunity (1/2)

    ADC-1013: Long term immunity (1/2) Mice can be cured from bladder cancer (MB49) by Cured mice are re-challenged with MB49 and LLC1, but ADC-1013 in hCD40tg mice receives no treatment Source: Company information 12

  13. Slide 13: ADC-1013: Long term immunity (2/2)

    ADC-1013: Long term immunity (2/2) Results from pre-clinical evaluation of ADC-1013 in treatment of MB49 bladder cancer 140 120 100 Tumor volume (mm³) 80 60 40 20 0 0 2 4 6 8 10 12 14 Time (days) Re-challenge with a different tumor Re-challenge with the same tumor Type LLC1 lung cancer Type MB49 bla

  14. Slide 14: ADC-1013: Partnership validating Alligator's model

    ADC-1013: Partnership validating Alligator’s model Partnership details for ADC-1013 Description of ongoing Phase I trial  40 patients with advanced solid tumors  5 clinical sites in the UK, DK and SE Description of agreement Royalty / Milestone potential Dosing & Primary Secondary  Exclusive worl

  15. Slide 15: ADC-1015: Bispecific OX40/CTLA-4 Ab in pre-clinical development

    ADC-1015: Bispecific OX40/CTLA-4 Ab in pre-clinical development ADC-1015 overview Clustering results in superior efficacy (T-cell activation) A D C -1 0 1 5 ( O X 4 0 / C T L A -4 a n tib o d y ) C o m b in a tio n o f m o n o s p e c ific  O X 4 0 a n d  C T L A -4 6000 CTLA-4 mediated clusteri

  16. Slide 16: Alligator highlights

    Alligator highlights Agonistic antibodies for tumor-directed immuno- oncology Well-positioned immuno-oncology pipeline Major out-licensing deal with Janssen Biotech State of the art technology platforms Human capital: Highly experienced immuno- oncology team 16

Alligator Bioscience — Carnegie Healthcare Seminar 2016 on 6ix